CG ONCOLOGY INC (CGON) Stock Fundamental Analysis
NASDAQ:CGON - Nasdaq - US1569441009 - Common Stock - Currency: USD
We assign a fundamental rating of 4 out of 10 to CGON. CGON was compared to 558 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CGON as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, CGON is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year CGON has reported negative net income.
CGON had a negative operating cash flow in the past year.
1.2 Ratios
CGON has a better Return On Assets (-14.50%) than 81.49% of its industry peers.
With an excellent Return On Equity value of -14.98%, CGON belongs to the best of the industry, outperforming 87.72% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.5% | ||
| ROE | -14.98% | ||
| ROIC | N/A |
ROA(3y)-25.11%
ROA(5y)N/A
ROE(3y)-27.89%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for CGON so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CGON does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CGON has more shares outstanding
There is no outstanding debt for CGON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 52.20 indicates that CGON is not in any danger for bankruptcy at the moment.
CGON has a Altman-Z score of 52.20. This is amongst the best in the industry. CGON outperforms 98.75% of its industry peers.
CGON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 52.2 |
ROIC/WACCN/A
WACC9.79%
2.3 Liquidity
A Current Ratio of 30.97 indicates that CGON has no problem at all paying its short term obligations.
CGON's Current ratio of 30.97 is amongst the best of the industry. CGON outperforms 97.51% of its industry peers.
A Quick Ratio of 30.97 indicates that CGON has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 30.97, CGON belongs to the best of the industry, outperforming 97.51% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 30.97 | ||
| Quick Ratio | 30.97 |
3. Growth
3.1 Past
CGON shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -31.90%.
CGON shows a strong growth in Revenue. In the last year, the Revenue has grown by 458.33%.
CGON shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -52.09% yearly.
EPS 1Y (TTM)-31.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)458.33%
Revenue growth 3Y-52.09%
Revenue growth 5YN/A
Sales Q2Q%-90.17%
3.2 Future
CGON is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.11% yearly.
The Revenue is expected to grow by 278.75% on average over the next years. This is a very strong growth
EPS Next Y-32.01%
EPS Next 2Y-14.06%
EPS Next 3Y19.36%
EPS Next 5Y31.11%
Revenue Next Year-56.26%
Revenue Next 2Y879.67%
Revenue Next 3Y491.86%
Revenue Next 5Y278.75%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CGON reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CGON. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CGON's earnings are expected to grow with 19.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.06%
EPS Next 3Y19.36%
5. Dividend
5.1 Amount
CGON does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
26.72
-0.39 (-1.44%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners97.07%
Inst Owner Change0%
Ins Owners1.17%
Ins Owner Change0%
Market Cap2.04B
Analysts81.25
Price Target64.01 (139.56%)
Short Float %16.05%
Short Ratio8.27
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.29%
Min EPS beat(2)-33.19%
Max EPS beat(2)-9.38%
EPS beat(4)2
Avg EPS beat(4)0.88%
Min EPS beat(4)-33.19%
Max EPS beat(4)26.21%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)210.02%
Min Revenue beat(2)-76.04%
Max Revenue beat(2)496.08%
Revenue beat(4)1
Avg Revenue beat(4)80.55%
Min Revenue beat(4)-76.04%
Max Revenue beat(4)496.08%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.8%
PT rev (3m)-6.11%
EPS NQ rev (1m)1.99%
EPS NQ rev (3m)-4.31%
EPS NY rev (1m)-1.93%
EPS NY rev (3m)-3.93%
Revenue NQ rev (1m)-8.73%
Revenue NQ rev (3m)-38.88%
Revenue NY rev (1m)-41.44%
Revenue NY rev (3m)-40.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3076.84 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.89 | ||
| P/tB | 2.89 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.51
EYN/A
EPS(NY)-1.85
Fwd EYN/A
FCF(TTM)-1.08
FCFYN/A
OCF(TTM)-1.08
OCFYN/A
SpS0.01
BVpS9.25
TBVpS9.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.5% | ||
| ROE | -14.98% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-25.11%
ROA(5y)N/A
ROE(3y)-27.89%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 457.69% | ||
| Cap/Sales | 35.95% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 30.97 | ||
| Quick Ratio | 30.97 | ||
| Altman-Z | 52.2 |
F-Score4
WACC9.79%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-31.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
EPS Next Y-32.01%
EPS Next 2Y-14.06%
EPS Next 3Y19.36%
EPS Next 5Y31.11%
Revenue 1Y (TTM)458.33%
Revenue growth 3Y-52.09%
Revenue growth 5YN/A
Sales Q2Q%-90.17%
Revenue Next Year-56.26%
Revenue Next 2Y879.67%
Revenue Next 3Y491.86%
Revenue Next 5Y278.75%
EBIT growth 1Y-106.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-63.28%
EBIT Next 3Y25.78%
EBIT Next 5YN/A
FCF growth 1Y-72.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-72.32%
OCF growth 3YN/A
OCF growth 5YN/A